+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5174533
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 118 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Adial Pharmaceuticals
  • Dupont
  • MediciNova
  • Merck sante
  • Odyssey pharmaceuticals
  • Tonix Pharmaceuticals
  • MORE
This ‘Alcohol Use Disorder-Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Alcohol Use Disorder in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Alcohol Use Disorder market report provides analysis regarding current treatment practices, approved therapies including Acamprosate (Campral), Disulfiram (Antabuse) and Naltrexone (Revia), emerging drugs like Ibudilast, AD04, TNX-102 SL market share of the individual therapies, and historical, current and forecasted Alcohol Use Disorder market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Alcohol Use Disorder treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Alcohol Use Disorder- Disease Understanding and Treatment Algorithm

Overview:

Alcohol use disorder (AUD) is a chronic heritable brain disorder with a variable clinical presentation. This variability, or heterogeneity, in clinical presentation, suggests complex interactions between environmental and biological factors, resulting in the development and progression of AUD. Classifying AUD into subgroups of common clinical or pathological characteristics would ease the complexity of teasing apart underlying molecular mechanisms.

Alcohol use disorder is characterized by loss of control over alcohol drinking that is accompanied by changes in brain regions related to the execution of motivated behaviors and the control of stress and emotionality. Mechanisms of positive and negative reinforcement both play imperative roles with individual drinking behavior being maintained by positive reinforcement (rewarding and desirable effects of alcohol) and/or negative reinforcement mechanisms.

To diagnose individuals with AUD, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition utilizes 11 criteria of excessive alcohol use, alcohol abuse, and alcohol dependence. Under DSM-5, the current version of the DSM, anyone meeting any two of the 11 criteria during the same 12-month period, receives a diagnosis of AUD. The severity of AUD - mild, moderate, or severe is based on the number of criteria met.

Treatment:

A multidisciplinary treatment approach is usually followed internationally for the management of AUD, which primarily includes psychosocial treatments, behavioral interventions, and pharmacotherapies. Some patients respond to psychosocial interventions and others to medication therapy alone, but most patients benefit from a combination of these approaches.

This chapter covers the details of conventional and current medical therapies available for the treatment of Alcohol Use Disorder. It also provides Alcohol Use Disorder treatment guidelines across the United States and Europe.

This Alcohol Use Disorder market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Alcohol Use Disorder treatment pattern and treatment guidelines in the US and Europe.

Epidemiology:

The Alcohol Use Disorder epidemiology chapters provide insights about historical and current Alcohol Use Disorder patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Alcohol Use Disorder epidemiology is segmented by the diagnosed prevalence of Alcohol Use Disorder, the gender-specific prevalence of Alcohol Use Disorder, and diagnosed prevalence of Alcohol Use Disorder by types. Besides, the report includes a thorough analysis of all segments.

According to the publisher’s, the total prevalent population of Alcohol Use Disorder in seven major markets was 25,774,817 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Alcohol Use Disorder were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Alcohol Use Disorder pipeline. It also helps understand the Alcohol Use Disorder clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The current treatment options for AUD include medication-assisted treatment, behavioral interventions, detox and psychosocial assistance from rehab and support groups. The only pharmacotherapies currently approved by the FDA for the treatment of AUD are disulfiram (Antabuse), acamprosate, oral naltrexone, and extended-release injectable naltrexone (Vivitrol).

Market Outlook:

The market size of Alcohol Use Disorder is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Alcohol Use Disorder market size. - Among EU5 countries, Germany, in 2017, had the largest market size with USD 78.19 million, while Italy had the smallest market size of USD 9.29 million.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Alcohol Use Disorder market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alcohol Use Disorder market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of AUD market is anticipated to experience a major positive shift in the coming years owing to the expected launch of AD04 (Adial Pharmaceuticals), Ibudilast (MediciNova) and TNX-102 SL (Tonix Pharmaceuticals)

Alcohol Use Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Alcohol Use Disorde.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Alcohol Use Disorder domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Alcohol Use Disorder Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights
  • In the coming years, Alcohol Use Disorder market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Alcohol Use Disorder Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Alcohol Use Disorder Pipeline Analysis
  • Alcohol Use Disorder Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Alcohol Use Disorder Report Key Strengths:
  • 11 years Forecast
  • 7MM Coverage
  • Alcohol Use Disorder Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Alcohol Use Disorder Report Assessment:
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Alcohol Use Disorder market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Alcohol Use Disorder total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Alcohol Use Disorder market size during the forecast period (2017-2030)?
  • At what CAGR, the Alcohol Use Disorder market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Alcohol Use Disorder market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Alcohol Use Disorder market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden and unmet needs of Alcohol Use Disorder?
  • What is the historical Alcohol Use Disorder patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Alcohol Use Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Alcohol Use Disorder?
  • Out of all 7MM countries, which country would have the highest prevalent population of Alcohol Use Disorder during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for Alcohol Use Disorder treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Alcohol Use Disorder in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Alcohol Use Disorder?
  • How many therapies are developed by each company for Alcohol Use Disorder?
  • How many are emerging therapies in mid-stage, and late stage of development for Alcohol Use Disorder treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alcohol Use Disorder therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alcohol Use Disorder and their status?
  • What are the key designations that have been granted for the emerging therapies for Alcohol Use Disorder?
  • What is the global historical and forecasted market of Alcohol Use Disorder?
Reasons to buy:
  • The report will help in developing business strategies by understanding trends shaping and driving the Alcohol Use Disorder market
  • To understand the future market competition in the Alcohol Use Disorder market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alcohol Use Disorder in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Alcohol Use Disorder market
  • To understand the future market competition in the Alcohol Use Disorder market
Which geography accounted for the largest Alcohol Use Disorder market size?
  • The United States accounted for the largest Alcohol Use Disorder market size.
What is forecasted Alcohol Use Disorder size in 2030?
  • The publisher estimates an increase in Alcohol Use Disorder Market Size during the study period, 2017-2030
What are the present Alcohol Use Disorder market drivers?
Poor efficacy of the approved therapies, diagnostic criteria (DSM5), absence of effective therapies, early detection of disease

What are the Alcohol Use Disorder market barriers?
  • Access to treatment, gender-related barriers, pessimistic attitudes toward treatments, unawareness of the severity
How many companies are developing drugs for Alcohol Use Disorder?
Currently, three key pharma players are developing the drug for Alcohol Use Disorder

Which are the leading companies in Alcohol Use Disorder market?
  • Key Players - Adial Pharmaceuticals, MediciNova, Tonix Pharmaceuticals
How is epidemiology segmented for Alcohol Use Disorder?
  • Diagnosed prevalence of Alcohol Use Disorder, gender-specific prevalence of Alcohol Use Disorder, and diagnosed prevalence of Alcohol Use Disorder by types
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adial Pharmaceuticals
  • Dupont
  • MediciNova
  • Merck sante
  • Odyssey pharmaceuticals
  • Tonix Pharmaceuticals
  • MORE
1 Key Insights

2 Executive Summary of Alcohol Use Disorder (AUD)

3 SWOT Analysis for Alcohol Use Disorder (AUD)

4 Alcohol Use Disorder (AUD) Market Overview at a Glance
4.1 Market Share (%) Distribution of AUD in 2017
4.2 Market Share (%) Distribution of AUD in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Definitions
5.3 Causes and risk factors
5.4 Subtypes of Alcoholics
5.5 Pathophysiology
5.6 Genetics of AUD
5.7 Diagnosis
5.8 Biomarkers

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Diagnosed Prevalent Population of Alcohol Use Disorder (AUD)

7 Country Wise-Epidemiology of Alcohol Use Disorder
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.4 Diagnosed Prevalence of AUD by Types in the United States
7.2 EU-5
7.2.1 Assumptions and Rationale
7.2.2 Germany
7.2.3 France
7.2.4 Italy
7.2.5 Spain
7.2.6 United Kingdom
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.4 Diagnosed Prevalence of AUD by Types in Japan

8 Treatment of AUD
8.1 Guidelines
American Psychiatric Association Guidelines
NICE Guidelines
8.2 Case study: Naltrexone for the Management of Alcohol Dependence
8.3 Patient Journey

9 Unmet Needs

10 Marketed Therapies
10.1 Acamprosate: Merck sante
10.1.1 Product Description
10.1.2 Regulatory milestones
10.1.3 Clinical Development activity
10.1.4 Safety and Efficacy
10.2 Disulfiram: Odyssey pharmaceuticals
10.2.1 Product Description
10.2.2 Regulatory milestones
10.2.3 Clinical Development activity
10.3 Naltrexone: Dupont
10.3.1 Product Description
10.3.2 Regulatory milestones
Product development activity
10.3.3 Clinical Development activity
10.3.4 Safety and Efficacy

11 Emerging Therapies
11.1 Ibudilast: MediciNova
11.1.1 Product Description
11.1.2 Product Development Activities
11.1.3 Clinical Development
11.1.4 Safety and Efficacy
11.2 AD04: Adial Pharmaceuticals
11.2.1 Product Description
11.2.2 Product Development Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.3 TNX-102: Tonix Pharmaceuticals
11.3.1 Product Description
11.3.2 Product Development Activities

12 Alcohol Use Disorder: 7 Major Market Analysis
12.1 Key Findings
12.2 Market Outlook:7MM
12.3 Market Size of Alcohol Use Disorder (AUD) in 7MM
12.4 United States
12.4.1 Total Market size of Alcohol Use Disorder (AUD)
12.4.2 Alcohol Use Disorder (AUD) Market Size by Therapies
12.5 EU5 Countries
12.5.1 Germany
12.5.2 France
12.5.3 Italy
12.5.4 Spain
12.5.5 United Kingdom
12.5.6 Japan

13 Market Drivers

14 Market Barriers

15 Appendix
15.1 Report Methodology

16 Publisher Capabilities

17 Disclaimer

18 About the Publisher

List of Tables
Table 1: Summary of Alcohol Use Disorder Market, Epidemiology, and Key Events (2017-2030)
Table 2: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017-2030)
Table 3: Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Table 4: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Table 5: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in the United States (2017-2030)
Table 6: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Table 7: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Table 8: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017-2030)
Table 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Table 10: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Table 11: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017-2030)
Table 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Table 13: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Table 14: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017-2030)
Table 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Table 16: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Table 17: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017-2030)
Table 18: Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Table 19: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Table 20: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017-2030)
Table 21: Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Table 22: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Table 23: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017-2030)
Table 24: Ibudilast, Clinical Trial Description, 2020
Table 25: AD04, Clinical Trial Description, 2020
Table 26: 7 Major Market Size of AUD in USD Million (2017-2030)
Table 27: The US Market size of AUD in USD Million (2017-2030)
Table 28: The US market size of AUD by Therapies in USD Million (2017-2030)
Table 29: Germany Market size of AUD in USD Million (2017-2030)
Table 30: Germany market size of AUD by Therapies in USD Million (2017-2030)
Table 31: France Market size of AUD in USD Million (2017-2030)
Table 32: France market size of AUD by Therapies in USD Million (2017-2030)
Table 33: Italy Market size of AUD in USD Million (2017-2030)
Table 34: Italy market size of AUD by Therapies in USD Million (2017-2030)
Table 35: Spain Market size of AUD in USD Million (2017-2030)
Table 36: Spain market size of AUD by Therapies in USD Million (2017-2030)
Table 37: UK Market size of AUD in USD Million (2017-2030)
Table 38: UK market size of AUD by Therapies in USD Million (2017-2030)
Table 39: Japan Market size of AUD in USD Million (2017-2030)
Table 40: Japan market size of AUD by Therapies in USD Million (2017-2030)

List of Figures
Figure 1: SWOT Analysis
Figure 2: Natural history of alcohol use disorders
Figure 3: Neuroimmune contributions to the cycle of addiction
Figure 4: Neuron-glia cell-cell interactions in neuroimmune responses to alcohol
Figure 5: AUDIT-C questionnaire
Figure 6: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017-2030)
Figure 7: Diagnosed Prevalence of AUD in the United States (2017-2030)
Figure 8: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Figure 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by type in the United States (2017-2030)
Figure 10: Diagnosed Prevalence of AUD in Germany (2017-2030)
Figure 11: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Figure 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017-2030)
Figure 13: Diagnosed Prevalence of AUD in France (2017-2030)
Figure 14: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Figure 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017-2030)
Figure 16: Diagnosed Prevalence of AUD in Italy (2017-2030)
Figure 17: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Figure 18: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017-2030)
Figure 19: Diagnosed Prevalence of AUD in Spain (2017-2030)
Figure 20: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Figure 21: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017-2030)
Figure 22: Diagnosed Prevalence of AUD in United Kingdom (2017-2030)
Figure 23: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Figure 24: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017-2030)
Figure 25: Diagnosed Prevalence of AUD in Japan (2017-2030)
Figure 26: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Figure 27: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017-2030)
Figure 28: Summary of available psychological treatments for AUD
Figure 29: Patient journey for Alcohol Use Disorder
Figure 30 Unmet needs for Alcohol Use Disorder
Figure 31: 7 Major Market Size of AUD in USD Million (2017-2030)
Figure 32: Market Size of AUD in the United States, USD Millions (2017-2030)
Figure 33: The US market size of AUD by therapies in USD Million (2017-2030)
Figure 34: Market Size of AUD in Germany, USD Millions (2017-2030)
Figure 35: Germany market size of AUD by therapies in USD Million (2017-2030)
Figure 36: Market Size of AUD in France, USD Millions (2017-2030)
Figure 37: France market size of AUD by therapies in USD Million (2017-2030)
Figure 38: Market Size of AUD in Italy, USD Millions (2017-2030)
Figure 39: Italy market size of AUD by therapies in USD Million (2017-2030)
Figure 40: Market Size of AUD in Spain, USD Millions (2017-2030)
Figure 41: Spain market size of AUD by therapies in USD Million (2017-2030)
Figure 42: Market Size of AUD in UK, USD Millions (2017-2030)
Figure 43: UK market size of AUD by therapies in USD Million (2017-2030)
Figure 44: Market Size of AUD in Japan, USD Millions (2017-2030)
Figure 45: Japan market size of AUD by therapies in USD Million (2017-2030)
Figure 46: Market Drivers
Figure 47 Market barriers for Alcohol Use Disorder
Note: Product cover images may vary from those shown
3 of 3
  • Merck sante
  • Odyssey pharmaceuticals
  • Dupont
  • MediciNova
  • Adial Pharmaceuticals
  • Tonix Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll